{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T02:32:52Z","timestamp":1795228372551,"version":"4.10.3"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>To describe healthcare resource utilization (HCRU) of patients with heart failure with preserved (HFpEF), mildly reduced (HFmrEF), and reduced ejection fraction (HFrEF) in Spain.\u00a0<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adults with\u2009\u2265\u20091 HF diagnosis and\u2009\u2265\u20091\u00a0year of continuous enrolment before the corresponding index date (1\/January\/2016) were identified through the BIG-PAC database. Rate per 100 person-years of all-cause and HF-related HCRU during the year after the index date were estimated using bootstrapping with replacement.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-one thousand two hundred ninety-seven patients were included, of whom 48.5% had HFrEF, 38.6% HFpEF and 4.2% HFmrEF, with the rest being of unknown EF. Mean age was 78.8\u2009\u00b1\u200911.8\u00a0years, 53.0% were men and 83.0% were in NYHA functional class II\/III. At index, 67.3% of patients were taking renin angiotensin system inhibitors, 61.2% beta blockers, 23.4% aldosterone antagonists and 5.2% SGLT2 inhibitors. Rates of HF-related outpatient visits and hospitalization were 968.8 and 51.6 per 100 person-years, respectively. Overall, 31.23% of patients were hospitalized, mainly because of HF (87.88% of total hospitalizations); HF hospitalization length 21.06\u2009\u00b1\u200917.49\u00a0days (median 16; 25th, 75th percentile 9\u201327). HF hospitalizations were the main cost component: inpatient 73.64%, pharmacy 9.67%, outpatient 9.43%, and indirect cost 7.25%. Rates of all-cause and HF-related HCRU and healthcare cost were substantial across all HF subgroups, being higher among HFrEF compared to HFmrEF and HFpEF patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>HCRU and cost associated with HF are high in Spain, HF hospitalizations being the main determinant. Medication cost represented only a small proportion of total costs, suggesting that an optimization of HF therapy may reduce HF burden.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12913-022-08614-x","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T08:04:34Z","timestamp":1665216274000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Healthcare resource utilization and costs among patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain"],"prefix":"10.1186","volume":"22","author":[{"given":"Carlos","family":"Escobar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hungta","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahila","family":"Justo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cid-Ruzafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip R.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan F.","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,8]]},"reference":[{"issue":"36","key":"8614_CR1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"8","key":"8614_CR2","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","volume":"145","author":"CW Tsao","year":"2022","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022;145(8):e153\u2013639.","journal-title":"Circulation"},{"issue":"15","key":"8614_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/amj.2020.03.03","volume":"5","author":"G Lippi","year":"2020","unstructured":"Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Med J. 2020;5(15):1\u20136. https:\/\/doi.org\/10.21037\/amj.2020.03.03.","journal-title":"AME Med J"},{"issue":"4","key":"8614_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.rce.2021.04.008","volume":"222","author":"C Escobar","year":"2022","unstructured":"Escobar C, Varela L, Palacios B, et al. Clinical characteristics, management, and one-year risk of complications among patients with heart failure with and without type 2 diabetes in Spain. Rev Clin Esp (Barc). 2022;222(4):195\u2013204.","journal-title":"Rev Clin Esp (Barc)"},{"issue":"1","key":"8614_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.recesp.2020.09.014","volume":"75","author":"A Sicras-Mainar","year":"2022","unstructured":"Sicras-Mainar A, Sicras-Navarro A, Palacios B, Varela L, Delgado JF. Epidemiology and treatment of heart failure in Spain: the HF-PATHWAYS study. Rev Esp Cardiol (Engl Ed). 2022;75(1):31\u20138.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"3","key":"8614_CR6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/ejhf.483","volume":"18","author":"EE van Riet","year":"2016","unstructured":"van Riet EE, Hoes AW, Wagenaar KP, Limburg A, Landman MA, Rutten FH. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail. 2016;18(3):242\u201352.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"8614_CR7","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/jamainternmed.2015.0924","volume":"175","author":"Y Gerber","year":"2015","unstructured":"Gerber Y, Weston SA, Redfield MM, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015;175(6):996\u20131004.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"8614_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s10741-017-9661-0","volume":"23","author":"AA Shafie","year":"2018","unstructured":"Shafie AA, Tan YP, Ng CH. Systematic review of economic burden of heart failure. Heart Fail Rev. 2018;23(1):131\u201345.","journal-title":"Heart Fail Rev"},{"issue":"8","key":"8614_CR9","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.jacc.2018.11.049","volume":"73","author":"J Butler","year":"2019","unstructured":"Butler J, Yang M, Manzi MA, et al. Clinical course of patients with worsening heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;73(8):935\u201344.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"8614_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","volume":"3","author":"G Savarese","year":"2017","unstructured":"Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3(1):7\u201311.","journal-title":"Card Fail Rev"},{"issue":"11","key":"8614_CR11","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004.","journal-title":"N Engl J Med"},{"issue":"21","key":"8614_CR12","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"15","key":"8614_CR13","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"2","key":"8614_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021;384(2):117\u201328.","journal-title":"N Engl J Med"},{"issue":"16","key":"8614_CR15","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"12","key":"8614_CR16","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2206286 Epub ahead of print.","journal-title":"N Engl J Med"},{"key":"8614_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.puhe.2022.03.019","volume":"207","author":"JS Bundgaard","year":"2022","unstructured":"Bundgaard JS, Mogensen UM, Christensen S, et al. Healthcare cost variation in patients with heart failure: a nationwide study. Public Health. 2022;207:88\u201393.","journal-title":"Public Health"},{"issue":"1","key":"8614_CR18","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1186\/s12913-020-05828-9","volume":"20","author":"C Escobar","year":"2020","unstructured":"Escobar C, Varela L, Palacios B, et al. Costs and healthcare utilisation of patients with heart failure in Spain. BMC Health Serv Res. 2020;20(1):964.","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"8614_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ehf2.12021","volume":"1","author":"MR Cowie","year":"2014","unstructured":"Cowie MR, Anker SD, Cleland JG, et al. Improving care for patients with acute heart failure: before, during and after hospitalization. ESC Heart Failure. 2014;1(2):110\u201345.","journal-title":"ESC Heart Failure"},{"issue":"3","key":"8614_CR20","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1002\/ehf2.13885","volume":"9","author":"T Hamada","year":"2022","unstructured":"Hamada T, Kubo T, Kawai K, et al. Clinical characteristics and frailty status in heart failure with preserved vs. reduced ejection fraction. ESC Heart Fail. 2022;9(3):1853\u201363.","journal-title":"ESC Heart Fail"},{"issue":"5","key":"8614_CR21","doi-asserted-by":"crossref","first-page":"16227","DOI":"10.20452\/pamw.16263","volume":"132","author":"TM Rywik","year":"2022","unstructured":"Rywik TM, Dory\u0144ska A, Wi\u015bniewska A, et al. Epidemiology and clinical characteristics of hospitalized heart failure patients with a reduced, mildly reduced and preserved ejection fraction. Pol Arch Intern Med. 2022;132(5):16227.","journal-title":"Pol Arch Intern Med"},{"issue":"1","key":"8614_CR22","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/ehf2.13742","volume":"9","author":"AR de Boer","year":"2022","unstructured":"de Boer AR, Vaartjes I, Gohar A, et al. Heart failure with preserved, mid-range, and reduced ejection fraction across health care settings: an observational study. ESC Heart Fail. 2022;9(1):363\u201372.","journal-title":"ESC Heart Fail"},{"issue":"12","key":"8614_CR23","doi-asserted-by":"publisher","first-page":"e018719","DOI":"10.1136\/bmjopen-2017-018719","volume":"7","author":"N Farr\u00e9","year":"2017","unstructured":"Farr\u00e9 N, Lupon J, Roig E, et al. Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain). BMJ Open. 2017;7(12):e018719.","journal-title":"BMJ Open"},{"issue":"5","key":"8614_CR24","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.hlc.2021.09.019","volume":"31","author":"C Tan","year":"2022","unstructured":"Tan C, Dinh D, Brennan A, et al. Characteristics and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction Compared to Heart Failure With Reduced Ejection Fraction: Insights From the VCOR Heart Failure Snapshot. Heart Lung Circ. 2022;31(5):623\u20138.","journal-title":"Heart Lung Circ"},{"issue":"2","key":"8614_CR25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41569-021-00605-5","volume":"19","author":"G Savarese","year":"2022","unstructured":"Savarese G, Stolfo D, Sinagra G, Lund LH. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol. 2022;19(2):100\u201316.","journal-title":"Nat Rev Cardiol"},{"key":"8614_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ijcard.2018.03.024","volume":"261","author":"N Olchanski","year":"2018","unstructured":"Olchanski N, Vest AR, Cohen JT, Neumann PJ, DeNofrio D. Cost comparison across heart failure patients with reduced and preserved ejection fractions: Analyses of inpatient decompensated heart failure admissions. Int J Cardiol. 2018;261:103\u20138.","journal-title":"Int J Cardiol"},{"key":"8614_CR27","doi-asserted-by":"crossref","unstructured":"Murphy TM, Waterhouse DF, James S, et al. A comparison of HFrEF vs HFpEF\u2019s clinical workload and cost in the first year following hospitalization and enrollment in a disease management program. Int J Cardiol. 2017;232:330\u20135.","DOI":"10.1016\/j.ijcard.2016.12.057"},{"issue":"7","key":"8614_CR28","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.amjcard.2015.07.018","volume":"116","author":"GA Nichols","year":"2015","unstructured":"Nichols GA, Reynolds K, Kimes TM, Rosales AG, Chan WW. Comparison of Risk of Re-hospitalization, All-Cause Mortality, and Medical Care Resource Utilization in Patients With Heart Failure and Preserved Versus Reduced Ejection Fraction. Am J Cardiol. 2015;116(7):1088\u201392.","journal-title":"Am J Cardiol"},{"issue":"1","key":"8614_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1253\/circrep.CR-21-0134","volume":"4","author":"R Kaichi","year":"2021","unstructured":"Kaichi R, Marume K, Nakai M, et al. Relationship Between Heart Failure Hospitalization Costs and Left Ventricular Ejection Fraction in an Advanced Aging Society. Circ Rep. 2021;4(1):48\u201358.","journal-title":"Circ Rep"},{"issue":"4","key":"8614_CR30","doi-asserted-by":"publisher","first-page":"282","DOI":"10.4274\/balkanmedj.galenos.2022.2022-3-97","volume":"39","author":"Y \u00c7avu\u015fo\u011flu","year":"2022","unstructured":"\u00c7avu\u015fo\u011flu Y, Altay H, Aras D, et al. Cost-of-disease of Heart Failure in Turkey: A Delphi Panel-based Analysis of Direct and Indirect Costs. Balkan Med J. 2022;39(4):282\u20139.","journal-title":"Balkan Med J"},{"key":"8614_CR31","doi-asserted-by":"publisher","first-page":"818525","DOI":"10.3389\/fcvm.2022.818525","volume":"9","author":"H Bueno","year":"2022","unstructured":"Bueno H, Go\u00f1i C, Salguero-Bodes R, et al. Primary vs. Secondary Heart Failure Diagnosis: Differences in Clinical Outcomes, Healthcare Resource Utilization and Cost. Front Cardiovasc Med. 2022;9:818525.","journal-title":"Front Cardiovasc Med"},{"issue":"7","key":"8614_CR32","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.recesp.2021.08.016","volume":"75","author":"H Bueno","year":"2022","unstructured":"Bueno H, Bernal JL, Jim\u00e9nez-Jim\u00e9nez V, et al. The Clinical outcomes, healthcare resource utilization, and related costs (COHERENT) model. Application in heart failure patients. Rev Esp Cardiol (Engl Ed). 2022;75(7):585\u201394.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"1","key":"8614_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/kisup.2012.64","volume":"3","author":"KDIGO","year":"2013","unstructured":"KDIGO. Chapter 1: Definition and classification of CKD. Kidney Int Suppl (2011). 2013;3(1):19\u201362.","journal-title":"Kidney Int Suppl (2011)"},{"key":"8614_CR34","unstructured":"The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC\/DDD): World Health Organization. Available at: https:\/\/www.who.int\/classifications-\/atcddd\/en\/. Last Accessed: July 2022."},{"issue":"8","key":"8614_CR35","doi-asserted-by":"publisher","first-page":"102413","DOI":"10.1016\/j.aprim.2022.102413","volume":"54","author":"FE Gonzalez-Loyola","year":"2022","unstructured":"Gonzalez-Loyola FE, Mu\u00f1oz MA, Navas E, Real J, Vinyoles E, Verd\u00fa-Rotellar JM. Burden of heart failure in primary healthcare. Aten Primaria. 2022;54(8):102413.","journal-title":"Aten Primaria"},{"issue":"10","key":"8614_CR36","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.recesp.2016.04.008","volume":"69","author":"J Com\u00edn-Colet","year":"2016","unstructured":"Com\u00edn-Colet J, Enjuanes C, Lup\u00f3n J, Cainzos-Achirica M, Badosa N, Verd\u00fa JM. Transitions of Care Between Acute and Chronic Heart Failure: Critical Steps in the Design of a Multidisciplinary Care Model for the Prevention of Rehospitalization. Rev Esp Cardiol (Engl Ed). 2016;69(10):951\u201361.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"6","key":"8614_CR37","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/1357633X19828130","volume":"26","author":"BS Bauer","year":"2020","unstructured":"Bauer BS, Nguyen-Phan AL, Ong MK, Ziaeian B, Nguyen KL. Cardiology electronic consultations: Efficient and safe, but consultant satisfaction is equivocal. J Telemed Telecare. 2020;26(6):341\u20138.","journal-title":"J Telemed Telecare"},{"issue":"1\u20132","key":"8614_CR38","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1177\/1357633X18796439","volume":"26","author":"S Jim\u00e9nez-Marrero","year":"2020","unstructured":"Jim\u00e9nez-Marrero S, Yun S, Cainzos-Achirica M, et al. Impact of telemedicine on the clinical outcomes and healthcare costs of patients with chronic heart failure and mid-range or preserved ejection fraction managed in a multidisciplinary chronic heart failure programme: A sub-analysis of the iCOR randomized trial. J Telemed Telecare. 2020;26(1\u20132):64\u201372.","journal-title":"J Telemed Telecare"},{"issue":"3","key":"8614_CR39","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cvdhj.2022.04.002","volume":"3","author":"N Shah","year":"2022","unstructured":"Shah N, Annam A, Cireddu N, Cireddu JV. VPExam Virtual Care for Heart Failure Optimizing Transitions of Care Quality Improvement Project (VPExam QI). Cardiovasc Digit Health J. 2022;3(3):146\u201355.","journal-title":"Cardiovasc Digit Health J"},{"issue":"3","key":"8614_CR40","doi-asserted-by":"publisher","first-page":"e054956","DOI":"10.1136\/bmjopen-2021-054956","volume":"12","author":"RM Masterson Creber","year":"2022","unstructured":"Masterson Creber RM, Daniels B, Munjal K, Reading Turchioe M, Shafran Topaz L, Goytia C, D\u00edaz I, Goyal P, Weiner M, Yu J, Khullar D, Slotwiner D, Ramasubbu K, Kaushal R. Using Mobile Integrated Health and telehealth to support transitions of care among patients with heart failure (MIGHTy-Heart): protocol for a pragmatic randomised controlled trial. BMJ Open. 2022;12(3):e054956.","journal-title":"BMJ Open"},{"issue":"11","key":"8614_CR41","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/ejhf.765","volume":"19","author":"HGC Van Spall","year":"2017","unstructured":"Van Spall HGC, Rahman T, Mytton O, et al. Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis. Eur J Heart Fail. 2017;19(11):1427\u201343.","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"8614_CR42","doi-asserted-by":"publisher","first-page":"e2027410","DOI":"10.1001\/jamanetworkopen.2020.27410","volume":"3","author":"A Baecker","year":"2020","unstructured":"Baecker A, Meyers M, Koyama S, et al. Evaluation of a Transitional Care Program After Hospitalization for Heart Failure in an Integrated Health Care System. JAMA Netw Open. 2020;3(12):e2027410.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"8614_CR43","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2459\/JCM.0000000000001221","volume":"23","author":"GMC Rosano","year":"2022","unstructured":"Rosano GMC, Vitale C, Adamo M, Metra M. Roadmap for the management of heart failure patients during the vulnerable phase after heart failure hospitalizations: how to implement excellence in clinical practice. J Cardiovasc Med (Hagerstown). 2022;23(3):149\u201356.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"2","key":"8614_CR44","first-page":"157","volume":"28","author":"KM Osenenko","year":"2022","unstructured":"Osenenko KM, Kuti E, Deighton AM, Pimple P, Szabo SM. Burden of hospitalization for heart failure in the United States: a systematic literature review. J Manag Care Spec Pharm. 2022;28(2):157\u201367.","journal-title":"J Manag Care Spec Pharm"},{"issue":"11","key":"8614_CR45","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s40273-020-00952-0","volume":"38","author":"M Urbich","year":"2020","unstructured":"Urbich M, Globe G, Pantiri K, et al. A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014\u20132020). Pharmacoeconomics. 2020;38(11):1219\u201336.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"8614_CR46","doi-asserted-by":"publisher","first-page":"e008943","DOI":"10.1161\/CIRCHEARTFAILURE.121.008943","volume":"15","author":"AMK Minhas","year":"2022","unstructured":"Minhas AMK, Ijaz SH, Jamal S, et al. Trends in Characteristics and Outcomes in Primary Heart Failure Hospitalizations Among Older Population in the United States, 2004 to 2018. Circ Heart Fail. 2022;15(5):e008943.","journal-title":"Circ Heart Fail"},{"issue":"5","key":"8614_CR47","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jchf.2022.01.021","volume":"10","author":"V Jain","year":"2022","unstructured":"Jain V, Minhas AMK, Khan SU, et al. Trends in HF Hospitalizations Among Young Adults in the United States From 2004 to 2018. JACC Heart Fail. 2022;10(5):350\u201362.","journal-title":"JACC Heart Fail"},{"issue":"1","key":"8614_CR48","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/XCE.0000000000000190","volume":"9","author":"N Olchanski","year":"2020","unstructured":"Olchanski N, Vest AR, Cohen JT, DeNofrio D. Comparing inpatient costs of heart failure admissions for patients with reduced and preserved ejection fraction with or without type 2 diabetes. Cardiovasc Endocrinol Metab. 2020;9(1):17\u201323.","journal-title":"Cardiovasc Endocrinol Metab"},{"key":"8614_CR49","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijcard.2019.10.033","volume":"307","author":"N Olchanski","year":"2020","unstructured":"Olchanski N, Vest AR, Cohen JT, DeNofrio D. Two-year outcomes and cost for heart failure patients following discharge from the hospital after an acute heart failure admission. Int J Cardiol. 2020;307:109\u201313.","journal-title":"Int J Cardiol"},{"key":"8614_CR50","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.amjcard.2022.01.047","volume":"171","author":"A Afzal","year":"2022","unstructured":"Afzal A, van Zyl J, Nisar T, et al. Trends in Hospital Admissions for Systolic and Diastolic Heart Failure in the United States Between 2004 and 2017. Am J Cardiol. 2022;171:99\u2013104.","journal-title":"Am J Cardiol"},{"issue":"5","key":"8614_CR51","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.recesp.2016.09.021","volume":"70","author":"J \u00c1lvarez-Garc\u00eda","year":"2017","unstructured":"\u00c1lvarez-Garc\u00eda J, Salamanca-Bautista P, Ferrero-Gregori A, et al. Prognostic Impact of Physician Specialty on the Prognosis of Outpatients With Heart Failure: Propensity Matched Analysis of the REDINSCOR and RICA Registries. Rev Esp Cardiol (Engl Ed). 2017;70(5):347\u201354.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"2","key":"8614_CR52","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10741-021-10097-7","volume":"27","author":"H Clark","year":"2022","unstructured":"Clark H, Rana R, Gow J, Pearson M, van der Touw T, Smart N. Hospitalisation costs associated with heart failure with preserved ejection fraction (HFpEF): a systematic review. Heart Fail Rev. 2022;27(2):559\u201372.","journal-title":"Heart Fail Rev"},{"issue":"5","key":"8614_CR53","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s11897-022-00559-w","volume":"19","author":"S Sukumar","year":"2022","unstructured":"Sukumar S, Orkaby AR, Schwartz JB, et al. Polypharmacy in Older Heart Failure Patients: a Multidisciplinary Approach. Curr Heart Fail Rep. 2022;19(5):290\u2013302.","journal-title":"Curr Heart Fail Rep."},{"key":"8614_CR54","doi-asserted-by":"publisher","unstructured":"Proudfoot C, Gautam R, Cristino J, Agrawal R, Thakur L, Tolley K. Model parameters influencing the cost-effectiveness of sacubitril\/valsartan in heart failure: evidence from a systematic literature review. Eur J Health Econ 2022 https:\/\/doi.org\/10.1007\/s10198-022-01485-3. Epub ahead of print.","DOI":"10.1007\/s10198-022-01485-3"},{"issue":"5","key":"8614_CR55","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.21037\/jtd-22-463","volume":"14","author":"X Lin","year":"2022","unstructured":"Lin X, Lin M, Liu M, Huang W, Nie X, Chen Z, Zheng B. Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection fraction: an analysis from the Chinese healthcare perspective. J Thorac Dis. 2022;14(5):1588\u201397.","journal-title":"J Thorac Dis"},{"key":"8614_CR56","doi-asserted-by":"publisher","first-page":"860109","DOI":"10.3389\/fphar.2022.860109","volume":"13","author":"M Wu","year":"2022","unstructured":"Wu M, Qin S, Wang L, et al. Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review. Front Pharmacol. 2022;13:860109.","journal-title":"Front Pharmacol"},{"issue":"3","key":"8614_CR57","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jchf.2021.11.006","volume":"10","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, Vaduganathan M, Claggett BL, et al. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial. JACC Heart Fail. 2022;10(3):184\u201397.","journal-title":"JACC Heart Fail"},{"issue":"8","key":"8614_CR58","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.recesp.2013.12.016","volume":"67","author":"JF Delgado","year":"2014","unstructured":"Delgado JF, Oliva J, Llano M, et al. Health care and nonhealth care costs in the treatment of patients with symptomatic chronic heart failure in Spain. Rev Esp Cardiol (Engl Ed). 2014;67(8):643\u201350.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"1","key":"8614_CR59","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1186\/s12889-018-6034-0","volume":"18","author":"B \u0141yszczarz","year":"2018","unstructured":"\u0141yszczarz B. Indirect costs and public finance consequences of heart failure in Poland, 2012\u20132015. BMC Public Health. 2018;18(1):1130.","journal-title":"BMC Public Health"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08614-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-022-08614-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08614-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T11:23:39Z","timestamp":1728127419000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-022-08614-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,8]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["8614"],"URL":"https:\/\/doi.org\/10.1186\/s12913-022-08614-x","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,8]]},"assertion":[{"value":"27 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were carried out in accordance with relevant guidelines and regulations. This study was approved by the Investigation Ethics Committee of HM Hospitales from Madrid on 17th December 2020. This was a secondary data study and data were fully anonymized and dissociated from patients. Therefore, there was no need for providing informed consent in Spain.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1241"}}